← Eichor
Condition: Hyperplasia Of Mammary Glands Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hyperplasia Of Mammary Glands

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Phase 2 · 3 location(s) · National Cancer Institute (NCI) · NCT06195306InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT05463796Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Phase N/A · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05178498Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Develop
Phase 2 · 4 location(s) · National Cancer Institute (NCI) · NCT05941520Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
Phase 3 · 27 location(s) · Tasly Pharmaceutical Group Co., Ltd · NCT06685978
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.